News

Kiadis Pharma receives IND approval from FDA to start pivotal clinical trial with ATIR™ 08-07-2010
Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR™ in the United States. Kiadis Pharma is currently... read more 

Kiadis Pharma Provides ATIR™ Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality - FDA grants ATIR™ Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related Mortality 28-04-2010
Kiadis Pharma today provided an update on its cell therapy product ATIR™ developed for mismatched bone marrow transplants. ATIR™ continues to show excellent clinical results in patients who received a mismatched bone marrow transplantation from a family member donor. The two year follow up data... read more 

Current investors

Kiadis Pharma is proud to be supported by a group of knowledgeable investors, contributing their expertise and network to enhance the development opportunities of the company.

LSP

LSP is a leading independent European biotech focused venture capital firm, providing private equity financing to early to mid stage life science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. With EUR 450 million under management and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors.

Alta Partners

Alta Partners is a San Francisco-based venture capital firm focused on life sciences investing. Founded in 1996, the firm currently manages $2 billion in committed capital through eight venture fund programs.
Alta invests in life sciences companies across the development continuum, from company formation to later-stage opportunities, and has funded more than 110 companies in the sector to date.

DFJ Esprit

DFJ Esprit is a venture capital fund backing extraordinary entrepreneurs and management teams in dynamic markets. DFJ Esprit is part of the Draper Fisher Jurvetson (DFJ) Global Network with 120 investment professionals in more than 30 cities around the world. With over 130 years of investing experience between its partners and over 130 investments made, DFJ Esprit has one of the most experienced teams and longest track records in European venture capital.

NOM

N.V. Nom, Investment and Development Agency for the Northern Netherlands, aims to make a contribution to the sustained improvement of the economic structure and employment in the Northern Netherlands. 

BioVeda

BioVeda provides venture capital financing to companies in the life sciences with leading proprietary technologies and outstanding scientific and management talent. BioVeda positions itself as a crucial business and scientific bridge between companies in the East and West, linking finance and technology between two very diverse markets.

Kiadis Pharma

Entrada 231-234
1096 EG  Amsterdam
The Netherlands


T +31 (0)20 314 02 50
F +31 (0)20 314 02 51